Abstract
Little is known about the mid-term outcomes of patients with atrial fibrillation (AF) who undergo coronary stenting in the second-generation drug-eluting stent (DES) era. We evaluated the 1-year outcomes of AF patients undergoing percutaneous coronary intervention (PCI) with second-generation DES. This retrospective cohort analysis used integrated data from the SHINANO registry, a prospective observational multicenter cohort study, which enrolled 1923 consecutive patients undergoing PCI for any coronary artery disease. We retrospectively recruited 917 of these patients (mean age, 71.3 ± 10.0 years; male, 77 %) who received PCI with 2nd generation DES. The primary endpoint was net adverse clinical events (NACE: cardiac death, stroke, MI, stent thrombosis, and major bleeding) at 1 year. The secondary endpoints were major adverse cardiovascular events (MACE: cardiac death, stroke, and MI), stroke, MI, and major bleeding at 1 year. One-year follow-up was completed in 871 (94.9 %) patients, of whom 85 had AF. The incidence of NACE (15.4 vs. 7.3 %, P = 0.008), MACE (10.6 vs. 5.4 %, P = 0.047), and major bleeding (6.0 vs. 2.3 %, P = 0.049) were all significantly higher in AF compared to non-AF patients. On multivariate analysis, AF was an independent predictor of NACE (HR 2.32, 95 % CI 1.24–4.34, P = 0.008). In the second-generation DES era, patients with AF undergoing PCI still have a poorer prognosis, with more thrombotic and bleeding events, than those without AF. More attention should be paid to the thrombotic and bleeding risk in AF patients undergoing PCI.
Similar content being viewed by others
Abbreviations
- AF:
-
Atrial fibrillation
- PCI:
-
Percutaneous coronary intervention
- CAD:
-
Coronary artery disease
- DES:
-
Drug-eluting stent(s)
- DAPT:
-
Dual antiplatelet therapy
- OAC:
-
Oral anticoagulants
- STEMI:
-
ST-segment elevation myocardial infarction
- NSTEMI:
-
Non-ST-segment elevation myocardial infarction
- UA:
-
Unstable angina
- MACE:
-
Major adverse cardiovascular events
- MI:
-
Myocardial infarction
- NACE:
-
Net adverse clinical events
- ACS:
-
Acute coronary syndrome
- TIMI:
-
Thrombolysis In Myocardial Infarction
- CK:
-
Creatine kinase
- HF:
-
Heart failure
- BP:
-
Blood pressure
- LVEF:
-
Left ventricular ejection fraction
- eGFR:
-
Estimated glomerular filtration rate (Cockcroft–Gault)
- PAD:
-
Peripheral artery disease
- CTO:
-
Chronic total occlusion
- BMS:
-
Bare-metal stent(s)
References
Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–5.
Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation—a multicenter study of its status and influential factors. Circ J. 2011;75:2087–94.
Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J. 2011;75:1328–33.
Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40:428–36.
Lin CJ, Liu CF, Kung CT, Sun CK, Lin YC, Leu S, et al. The prognostic value of atrial fibrillation on 30-day clinical outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int Heart J. 2011;52:153–8.
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103:13–28.
Schlitt A, Rubboli A, Lip GY, Lahtela H, Valencia J, Karjalainen PP, et al. AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group). The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. Catheter Cardiovasc Interv. 2013;82:E864–70.
Goto K, Nakai K, Shizuta S, Morimoto T, Shiomi H, Natsuaki M, CREDO-Kyoto Registry Cohort-2 Investigators, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2014;114:70–8.
Goto S, Bhatt DL, Röther J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothtombosis. Am Heart J. 2008;156(5):855–63.
Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, WOEST study investigators, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.
Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–97.
Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid A, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015;65:1092–102.
Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–79.
Miura T, Miyashita Y, Motoki H, Shimada K, Kobayashi M, Nakajima H, et al. In-hospital clinical outcomes of elderly patients (≥80 years) undergoing percutaneous coronary intervention. Circ J. 2014;78:1097–103.
Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196–203.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;2014(64):e1–76.
Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Nammas W, et al. Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronaray intervention. Circ J. 2014;78:2674–81.
Acknowledgments
We appreciate the supports of the co-investigators participating in the Shinano-registry.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors has a real or perceived conflict of interest regarding the work presented in this manuscript.
Human right statement
Written informed consents were obtained from all the study patients.
Rights and permissions
About this article
Cite this article
Miura, T., Miyashita, Y., Motoki, H. et al. Comparison of mid-term outcomes between patients with and without atrial fibrillation undergoing coronary stenting in the second-generation drug-eluting stent era: from the SHINANO registry. Cardiovasc Interv and Ther 32, 206–215 (2017). https://doi.org/10.1007/s12928-016-0406-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12928-016-0406-0